[Analysis of hematological findings affecting the efficiency of the autologous peripheral blood stem cells harvest].
As a predictor of the timing of peripheral blood stem cell harvest (PBSCH) and the yields of PBSC, the efficacy of measurement of CD34+ cell count in PB has been reported. However this measurement is difficult to carry out on the day of PBSCH in most general hospitals because of not having their own flow cytometry. Therefore in order to evaluate the usefulness of several clinical factors which are easily performed in general hospitals as a guide for PBSCH, we analyzed the correlation between these factors and the harvest efficiency (HE) of PBSCH. Eighty-one PBSCHs mobilized by chemotherapy with granulocyte colony-stimulating factor (G-CSF)(n = 63) or chemotherapy alone (n = 18) were carried out in 33 patients with various malignancies. In the group of PBSCHs mobilized by chemotherapy with G-CSF, a strong correlation was observed between HE and the percentage of immature cells in peripheral WBC (IMA-%) on the harvest day (r = 0.724), and between HE and the count of immature cells in PB (IMA-Co) on the same harvest day (r = 0.629). However routine blood counts, except IMA-% and IMA-Co, and the time (days) required for hemopoietic recovery after mobilizing chemotherapy did not correlate with HE. In the group of PBSCHs mobilized by chemotherapy alone, several hematological findings (WBC count, monocyte count and %, IMA-Co, platelet count, reticulocyte-@1000) on the harvest day and recovering velocity of WBC and platelet correlated with HE. These findings suggested that IMA-% and IMA-Co were the most useful factors for successful PBSCH widely mobilized by chemotherapy with G-CSF in general hospitals.
Nakata
K
K
Unit of Blood Transfusion Medicine, University Hospital, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu 807-8555, Japan.
Sakamoto
H
H
D018952:Antigens, CD34 / Q000032:analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007937:Leukapheresis; D007958:Leukocyte Count; D014182:Transplantation, Autologous
D018952:Antigens, CD34; D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor